Clinical Genomics Licenses Biomarkers from Garvan Institute

The Sydney, Australia-based firm obtained worldwide, exclusive rights to Garvan's cancer-associated methylation DNA biomarkers for the diagnosis and/or treatment of colorectal cancer.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories